Zometa (zoledronic acid) is an intravenous medication used to treat cancer-related bone problems. It has two main uses: lowering dangerously high calcium levels caused by cancer, and reducing bone damage in patients with multiple myeloma or cancer that has spread to the bones. It belongs to a class of drugs called bisphosphonates, which work by slowing the breakdown of bone tissue.
Cancer-Related Bone Damage
When cancer spreads to bone, or when a blood cancer like multiple myeloma grows within bone, it can weaken the skeleton and lead to fractures, spinal cord compression, and severe pain. These complications are collectively called skeletal-related events. Zometa is given alongside standard cancer treatment to reduce the frequency of these events in patients with multiple myeloma or bone metastases from solid tumors like breast, lung, or prostate cancer. For prostate cancer specifically, the disease must have continued progressing despite at least one round of hormonal therapy before Zometa is started.
In patients with multiple myeloma, Zometa reduced the risk of skeletal-related events by 26% compared to an older bisphosphonate. That translates to treating roughly 6 to 15 patients to prevent one major bone complication in one of them. While those numbers may sound modest, a single avoided fracture or spinal compression can make a significant difference in quality of life during cancer treatment.
Hypercalcemia of Malignancy
Some cancers cause calcium to flood into the bloodstream, a condition called hypercalcemia of malignancy. Symptoms range from nausea, confusion, and extreme thirst to dangerous heart rhythm changes. Zometa is used when blood calcium levels rise to 12 mg/dL or higher (after adjusting for protein levels). It works by putting the brakes on the process that pulls calcium out of bone and into the blood, helping levels return to a safe range.
How Zometa Works in the Body
Bone is constantly being remodeled. Specialized cells called osteoclasts break down old bone, while other cells rebuild it. In cancer patients, this balance tips sharply toward breakdown: tumors in or near bone can accelerate osteoclast activity, weakening the skeleton and flooding the blood with calcium. Zometa has a strong natural affinity for bone tissue. Once it reaches bone surfaces, it disrupts the chemical pathway osteoclasts rely on to function. It blocks a key enzyme in that pathway, which both prevents new osteoclasts from maturing and triggers existing ones to self-destruct. The net effect is a significant slowdown in bone destruction.
How It Is Given
Zometa is delivered as an intravenous infusion, typically over at least 15 minutes. The standard dose for bone metastases and multiple myeloma is 4 mg, given once every three to four weeks. For hypercalcemia of malignancy, a single 4 mg infusion is the usual starting approach. Each session is short enough that it can be done during a routine oncology visit.
Patients receiving Zometa for bone metastases or myeloma are also typically asked to take a daily oral calcium supplement (500 mg) and a multivitamin containing 400 IU of vitamin D. This helps maintain healthy calcium balance while the drug reduces bone turnover.
Kidney Monitoring
Zometa is cleared through the kidneys, so kidney function is checked before each infusion. Patients with mildly or moderately reduced kidney function receive a lower dose, scaled down based on their kidney filtration rate. Those with severe kidney impairment are generally not candidates for Zometa when it’s being used for bone metastases, because there isn’t enough safety data in that group. For hypercalcemia, the decision is more flexible: dose adjustments aren’t required for mild to moderate kidney problems, though severe impairment calls for a careful risk-benefit discussion.
Osteonecrosis of the Jaw
The most notable risk unique to Zometa is osteonecrosis of the jaw, a condition where a patch of jawbone loses its blood supply and becomes exposed through the gum. A large study of cancer patients on zoledronic acid found the risk was about 1% after one year of treatment, 2% after two years, and 3% after three years. The rate varied by cancer type, reaching 4.3% in people with multiple myeloma and dropping to 2.4% in those with breast cancer that had spread to bone.
The condition is defined as an area of exposed jawbone that persists for at least eight weeks. Because dental procedures can raise the risk, oncologists typically recommend completing any needed dental work before starting Zometa. Good oral hygiene and regular dental checkups during treatment also help reduce the likelihood.
Zometa vs. Reclast
Zoledronic acid is also sold under the brand name Reclast for treating osteoporosis in people without cancer. The two products contain the same active ingredient but are prescribed for very different conditions at different doses and schedules. Zometa is specifically the oncology formulation, dosed more frequently (every few weeks) for cancer-related bone problems. Reclast is given once a year for osteoporosis. The two are not interchangeable.